National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Jump to:
loading...
Preferred Name

Brentuximab
Synonyms

Monoclonal Antibody SGN-30

Anti-CD30 Monoclonal Antibody

BRENTUXIMAB

Brentuximab

CAC-10

CAC10

SGN-30

SGN30
Definitions

A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.
ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C2007
ALT_DEFINITION

A monoclonal antibody that binds to cells that have the CD30 antigen on their surface, including Hodgkin disease cells and cells from anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. SGN-30 is being studied in the treatment of cancer. It is a type of monoclonal antibody.
CAS_Registry

775303-41-8
code

C2007
Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537
Contributing_Source

CTRP

FDA

GDC
DEFINITION

A genetically-engineered, chimeric mouse-human, anti-CD30 monoclonal antibody with potential antineoplastic activity. Brentuximab specifically binds to the receptor CD-30, a member of the tumor necrosis factor receptor super-family, which may be overexpressed on the surfaces of Hodgkin lymphoma cells and anaplastic-large cell lymphoma cells. After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.
Display_Name

Brentuximab
FDA_UNII_Code

C67ORA155P
FULL_SYN

Monoclonal Antibody SGN-30

Anti-CD30 Monoclonal Antibody

BRENTUXIMAB

Brentuximab

CAC-10

CAC10

SGN-30

SGN30
Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38906
Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909
label

Brentuximab
Legacy Concept Name

SGN-30
Maps_To

Brentuximab
NCI_Drug_Dictionary_ID

357600
NSC Number

731636
PDQ_Closed_Trial_Search_ID

357600
PDQ_Open_Trial_Search_ID

357600
Preferred_Name

Brentuximab
prefixIRI

Thesaurus:C2007
Semantic_Type

Amino Acid, Peptide, or Protein

Pharmacologic Substance

Immunologic Factor
UMLS_CUI

C1328236
subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129822

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164002
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display